RxDoctor Payments Data

Vikram Durairaj, MD

Ophthalmic Plastic and Reconstructive Surgery · Austin, TXNPI 1871683540

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Stryker at 55.2% of the total. Reporting peaked in 2022 at $123,714 and has fallen 67.2% since, to $40,531 in 2025. Among ophthalmic plastic and reconstructive surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$378,572in general payments, 2019–2025

Across 393 payments — averaging $963.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$209K
  • Genentech USA, Inc.$127K
  • Amgen$26K
  • Sun Pharmaceutical Industries Inc.$10K
  • Lumenis BE Inc$2K
  • Tarsus Pharmaceuticals, Inc.$609
  • plus $4K from 20 others

What the payments were for

  • Consulting fees$192,46151%
  • Speaking & faculty fees$120,72532%
  • Travel & lodging$50,10113%
  • Food & beverage$15,1064%
  • Education$340%
  • Entertainment$1440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$378,572 in reported general payments places this provider in the 95th percentile of 36 ophthalmic plastic and reconstructive surgery providers in Texas.

See all ophthalmic plastic and reconstructive surgery providers in Texas

Medicare billing

Part B allowed, 2024
$270,330
Medicare patients
398
Services billed
1,786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErythromycinErythromycin Base349$3,801
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha91$964
Prednisolone Acetate32$846
Acetaminophen-CodeineAcetaminophen With Codeine179$508
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$412
Methylprednisolone58$362
ValacyclovirValacyclovir Hcl15$140

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →